Abstract
In a 12-month double-blind placebo-controlled trial, the effect of sulphasalazine was studied in 40 patients with ankylosing spondylitis. The treatment group showed significant improvement in pain, stiffness, sleep disturbance (p less than 0.05), finger/floor distance, erythrocyte sedimentation rate, C-reactive protein, orosomucoid and IgA levels (p less than 0.01). There was improvement in sleep disturbance (p less than 0.05), finger/floor distance and erythrocyte sedimentation rate (p less than 0.01) in the placebo group. Sulphasalazine did not retard radiological progression as measured either by plain X-ray or computerised tomographic scans. Multiple analysis of variance did not show a significant difference in disease activity indicators between the 2 groups.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Analysis of Variance
-
Anti-Inflammatory Agents, Non-Steroidal / pharmacology
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Blood Sedimentation / drug effects
-
C-Reactive Protein / metabolism
-
Cohort Studies
-
Double-Blind Method
-
Haptoglobins / metabolism
-
Humans
-
Immunoglobulin A / metabolism
-
Orosomucoid / metabolism
-
Spondylitis, Ankylosing / diagnostic imaging
-
Spondylitis, Ankylosing / drug therapy*
-
Spondylitis, Ankylosing / metabolism
-
Spondylitis, Ankylosing / pathology
-
Sulfasalazine / pharmacology
-
Sulfasalazine / therapeutic use*
-
Tomography, X-Ray Computed
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Haptoglobins
-
Immunoglobulin A
-
Orosomucoid
-
Sulfasalazine
-
C-Reactive Protein